Status:
COMPLETED
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
Lead Sponsor:
Bayer
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
18+ years
Brief Summary
In this international non-interventional study safety and clinical data concerning the treatment of patients suffering from Hepatocellular Carcinoma (HCC) will be collected.
Eligibility Criteria
Inclusion
- Outpatients with histologically/cytologically documented or radiographically diagnosed unresectable HCC who are candidates for systemic therapy and for whom a decision to treat with Nexavar has been made. Radiographic diagnosis HCC NIS, needs typical findings of HCC by radiographic method i.e. on multi-dimensional, dynamic CT, CT hepatic arteriography (CTHA)/CT arterial portography (CTAP), or MRI.
- Patients must have signed an informed consent form
- Patients must have a life expectancy of at least 8 weeks
Exclusion
- Exclusion criteria must follow the approved local product information
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
3371 Patients enrolled
Trial Details
Trial ID
NCT00812175
Start Date
January 1 2009
End Date
April 1 2012
Last Update
October 17 2016
Active Locations (75)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Alabama, United States
2
Many Locations, Arizona, United States
3
Many Locations, Arkansas, United States
4
Many Locations, California, United States